IV-01 Khaled Abduljalil Prediction of Tolerance to Caffeine Pressor Effect during Pregnancy using Physiologically Based PK-PD Modelling Thursday 14:55-16:20 |
IV-02 Rick Admiraal Exposure to the biological anti-thymocyte globulin (ATG) in children receiving allogeneic-hematopoietic cell transplantation (HCT): towards individualized dosing to improve survival Thursday 14:55-16:20 |
IV-03 Wafa Alfwzan Mathematical Modelling of the Spread of Hepatitis C among Drug Users, effects of heterogeneity. Thursday 14:55-16:20 |
IV-04 Sarah Alghanem Comparison of NONMEM and Pmetrics Analysis for Aminoglycosides in Adult Patients with Cystic Fibrosis Thursday 14:55-16:20 |
IV-05 Nidal Huniti A Nonlinear Mixed Effect Model to Describe Placebo Response in Children and Adolescents with Major Depressive Disorder Thursday 14:55-16:20 |
IV-06 Hesham Al-Sallami Evaluation of a Bayesian dose-individualisation method for enoxaparin Thursday 14:55-16:20 |
IV-07 Oskar Alskär Modelling of glucose absorption Thursday 14:55-16:20 |
IV-08 Helena Edlund Clinical relevance of albumin concentration in patients with Crohn’s disease treated with infliximab for recommendations on dosing regimen adjustments Thursday 14:55-16:20 |
IV-09 Franc Andreu Solduga Development of a Bayesian Estimator for Tacrolimus in Kidney Transplant Patients: A Population Pharmacokinetic approach. Thursday 14:55-16:20 |
IV-10 Yasunori Aoki PopED lite an easy to use experimental design software for preclinical studies Thursday 14:55-16:20 |
IV-11 Eduardo Asín-Prieto Population Pharmacokinetics of Cefuroxime in patients Undergoing Colorectal Surgery Thursday 14:55-16:20 |
IV-12 Ioanna Athanasiadou Simulation of the effect of hyperhydration on urine levels of recombinant human erythropoietin from a doping control point of view Thursday 14:55-16:20 |
IV-13 Guillaume Baneyx Modeling Erlotinib and Gefitinib in Vitro Penetration through Multiple Layers of Epidermoid and Colorectal Human Carcinoma Cells Thursday 14:55-16:20 |
IV-14 Aliénor Bergès Dose selection in Amyotrophic Lateral Sclerosis: PK/PD model using laser scanning cytometry data from muscle biopsies in a patient study Thursday 14:55-16:20 |
IV-15 Shanshan Bi Population Pharmacokinetic/Pharmacodynamic Modeling of Two Novel Neutral Endopeptidase Inhibitors in Healthy Subjects Thursday 14:55-16:20 |
IV-16 Bruno Bieth Population Pharmacokinetics of QVA149, the fixed dose combination of Indacaterol maleate and Glycopyrronium bromide in Chronic Obstructive Pulmonary Disease (COPD) patients Thursday 14:55-16:20 |
IV-17 Roberto Bizzotto Characterization of binding between OSM and mAb in RA patient study: an extension to TMDD models Thursday 14:55-16:20 |
IV-18 Marcus Björnsson Effect on bias in EC50 when using interval censoring or exact dropout times in the presence of informative dropout Thursday 14:55-16:20 |
IV-19 Karina Blei Mechanism of Action of Jellyfish (Carukia barnesi) Envenomation and its Cardiovascular Effects Resulting in Irukandji Syndrome Thursday 14:55-16:20 |
IV-20 Michael Block Predicting the antihypertensive effect of Candesartan-Nifedipine combinations based on public benchmarking data. Thursday 14:55-16:20 |
IV-21 Michael Block Physiologically-based PK/PD modeling for a dynamic cardiovascular system: structure and applications Thursday 14:55-16:20 |
IV-22 Irina Bondareva Population Modeling of the Time-dependent Carbamazepine (CBZ) Autoinduction Estimated from Repeated Therapeutic Drug Monitoring (TDM) Data of Drug-naïve Adult Epileptic Patients Begun on CBZ-monotherapy Thursday 14:55-16:20 |
IV-23 Jens Markus Borghardt Characterisation of different absorption rate constants after inhalation of olodaterol Thursday 14:55-16:20 |
IV-25 Karl Brendel How to deal properly with change-point model in NONMEM? Thursday 14:55-16:20 |
IV-26 Frances Brightman Predicting Torsades de Pointes risk from data generated via high-throughput screening Thursday 14:55-16:20 |
IV-27 Margreke Brill Population pharmacokinetic model for protein binding and subcutaneous adipose tissue distribution of cefazolin in morbidly obese and non-obese patients Thursday 14:55-16:20 |
IV-28 Brigitte Brockhaus Semi-mechanistic model-based drug development of EMD 525797 (DI17E6), a novel anti-αv integrin monoclonal antibody Thursday 14:55-16:20 |
IV-30 Vincent Buchheit Data quality impacts on modeling results Thursday 14:55-16:20 |
IV-31 Núria Buil Bruna Modelling LDH dynamics to assess clinical response as an alternative to tumour size in SCLC patients Thursday 14:55-16:20 |
IV-33 Theresa Cain Prediction of Rosiglitazone compliance from last sampling information using Population based PBPK modelling and Bayes theorem: Comparison of prior distributions for compliance. Thursday 14:55-16:20 |
IV-34 Vicente G. Casabo Modification Of Non Sink Equation For Calculation The Permeability In Cell Monolayers Thursday 14:55-16:20 |
IV-35 Anne Chain Not-In-Trial Simulations: A tool for mitigating cardiovascular safety risks Thursday 14:55-16:20 |
IV-36 Kalayanee Chairat A population pharmacokinetics and pharmacodynamics of oseltamivir and oseltamivir carboxylate in adults and children infected with influenza virus A(H1N1)pdm09 Thursday 14:55-16:20 |
IV-37 Quentin Chalret du Rieu Hematological toxicity modelling of abexinostat (S-78454, PCI-24781), a new histone deacetylase inhibitor, in patients suffering from solid tumors or lymphoma: influence of the disease-progression on the drug-induced thrombocytopenia. Thursday 14:55-16:20 |
IV-38 Phylinda Chan Industry Experience in Establishing a Population Pharmacokinetic Analysis Guidance Thursday 14:55-16:20 |
IV-39 Pascal Chanu Simulation study for a potential sildenafil survival trial in adults with pulmonary arterial hypertension (PAH) using a time-varying exposure-hazard model developed from data in children Thursday 14:55-16:20 |
IV-40 Christophe Chassagnole Virtual Tumour Clinical: Literature example Thursday 14:55-16:20 |
IV-41 Chao Chen A mechanistic model for the involvement of the neonatal Fc receptor in IgG disposition Thursday 14:55-16:20 |
IV-42 Chunli Chen Design optimization for characterization of rifampicin pharmacokinetics in mouse Thursday 14:55-16:20 |
IV-43 Nianhang Chen Comparison of Two Parallel Computing Methods (FPI versus MPI) in NONMEM 7.2 on complex popPK and popPK/PD Models Thursday 14:55-16:20 |
IV-44 Marylore Chenel Population Pharmacokinetic Modelling to Detect Potential Drug Interaction Using Sparse Sampling Data Thursday 14:55-16:20 |
IV-45 Jason Chittenden Practical Application of GPU Computing to Population PK Thursday 14:55-16:20 |
IV-46 Yu-Yuan Chiu Exposure-Efficacy Response Model of Lurasidone in Patients with Bipolar Depression Thursday 14:55-16:20 |
IV-47 Steve Choy Modelling the Effect of Very Low Calorie Diet on Weight and Fasting Plasma Glucose in Type 2 Diabetic Patients Thursday 14:55-16:20 |
IV-48 Oskar Clewe A Model Predicting Penetration of Rifampicin from Plasma to Epithelial Lining Fluid and Alveolar Cells Thursday 14:55-16:20 |
IV-49 Teresa Collins Performance of Sequential methods under Pre-clinical Study Conditions Thursday 14:55-16:20 |
IV-50 Francois Combes Influence of study design and associated shrinkage on power of the tests used for covariate detection in population pharmacokinetics Thursday 14:55-16:20 |
IV-51 Emmanuelle Comets Additional features and graphs in the new npde library for R Thursday 14:55-16:20 |
IV-52 Camille Couffignal Population pharmacokinetics of imipenem in intensive care unit patients with ventilated-associated pneumonia Thursday 14:55-16:20 |
IV-53 Damien Cronier PK/PD relationship of the monoclonal anti-BAFF antibody tabalumab in combination with bortezomib in patients with previously treated multiple myeloma: comparison of serum M-protein and serum Free Light Chains as predictor of Progression Free Survival Thursday 14:55-16:20 |
IV-54 Zeinab Daher Abdi Analysis of the relationship between Mycophenolic acid (MPA) exposure and anemia using three approaches: logistic regression based on Generalized Linear Mixed Models (GLMM) or on Generalized Estimating Equations (GEE) and Markov mixed-effects model. Thursday 14:55-16:20 |
IV-55 Elyes Dahmane Population Pharmacokinetics of Tamoxifen and three of its metabolites in Breast Cancer patients Thursday 14:55-16:20 |
IV-56 Adam Darwich A physiologically based pharmacokinetic model of oral drug bioavailability immediately post bariatric surgery Thursday 14:55-16:20 |
IV-57 Camila De Almeida Modelling Irinotecan PK, efficacy and toxicities pre-clinically Thursday 14:55-16:20 |
IV-58 Willem de Winter Population PK/PD analysis linking the direct acute effects of canagliflozin on renal glucose reabsorption to the overall effects of canagliflozin on long-term glucose control using HbA1c as the response marker from clinical studies Thursday 14:55-16:20 |
IV-59 Joost DeJongh A population PK-PD model for effects of Sipoglitazar on FPG and HbA1c in patients with type II diabetes. Thursday 14:55-16:20 |
IV-60 Paolo Denti A semi-physiological model for rifampicin and rifapentine CYP3A induction on midazolam pharmacokinetics. Thursday 14:55-16:20 |
IV-61 Cheikh Diack An indirect response model with modulated input rate to characterize the dynamics of Aβ-40 in cerebrospinal fluid Thursday 14:55-16:20 |
IV-62 Laura Dickinson Population Pharmacokinetics of Twice Daily Zidovudine (ZDV) in HIV-Infected Children and an Assessment of ZDV Exposure Following WHO Dosing Guidelines Thursday 14:55-16:20 |
IV-63 Christian Diedrich Using Bayesian-PBPK Modeling for Assessment of Inter-Individual Variability and Subgroup Stratification Thursday 14:55-16:20 |
IV-64 Christian Diestelhorst Population Pharmacokinetics of Intravenous Busulfan in Children: Revised Body Weight-Dependent NONMEM® Model to Optimize Dosing Thursday 14:55-16:20 |
IV-65 Aris Dokoumetzidis Bayesian parameter scan for determining bias in parameter estimates Thursday 14:55-16:20 |